Summarized by Daily Strand AI from peer-reviewed source
When scientists talk about supercharging the immune system to fight cancer, they usually focus on T cells — the attack dogs of immunity. But a growing body of research suggests that B cells, best known for producing antibodies, are playing a surprisingly complex and important role in melanoma, the deadliest form of skin cancer. A new review article pulls together the emerging evidence, and the picture it paints is one of a system working at cross-purposes with itself.
It turns out that not all B cells are on the patient's side. Some B cell subtypes — particularly so-called regulatory B cells, or Bregs — actively suppress the immune response by releasing chemical signals (proteins called TGFβ and IL-10) that calm down other immune fighters and help the tumor hide. Making matters worse, some B cells produce antibodies of a type called IgG4, which are essentially inert — they can tag a tumor cell but don't trigger the immune system to destroy it. On the other hand, a different class of B cells tells a more hopeful story. Mature 'memory' B cells and clusters of immune cells that organize themselves inside tumors into structures called tertiary lymphoid structures (think of them as pop-up lymph nodes inside the tumor itself) appear to be associated with better responses to checkpoint inhibitor therapy — the class of immunotherapy drugs that essentially 'unlock' the immune system's brakes. The review also notes that B cells inside tumors show signs of intense activity, including genetic changes that fine-tune antibodies, but some of this activity looks disordered, resembling the kind of misdirected immune response seen in autoimmune diseases.
Checkpoint inhibitor drugs like pembrolizumab and nivolumab have transformed melanoma treatment — a disease that was once nearly untreatable at advanced stages now has meaningful long-term survival rates for some patients. But a substantial proportion of patients still don't respond, and doctors currently have limited tools to predict who will benefit and who won't. This review argues that B cell profiles — measurable in blood samples — could serve as biomarkers to identify which patients are likely to respond to treatment, and which may be at higher risk for immune-related side effects, where the revved-up immune system starts attacking healthy tissue. The authors suggest that targeting regulatory B cells, correcting the imbalance toward inert antibody types, and monitoring changes in B cell behavior during therapy could all represent meaningful opportunities to improve outcomes. It's important to note, however, that this is a review of existing research rather than new clinical trial data, and the relationships described are largely associative — meaning scientists can see these patterns correlating with outcomes, but haven't yet proven direct cause and effect. Larger prospective clinical trials will be needed before these insights translate into changes at the bedside.
Interested in Oncology?
Newsletter
Never miss a breakthrough.
Join 10,000+ curious minds getting biotech stories distilled into plain language. Free, three times a week.